Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
01:54pm, Friday, 05'th Feb 2021
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
07:05pm, Thursday, 28'th Jan 2021
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline
Is the Options Market Predicting a Spike in Mesoblast (MESO) Stock?
09:47am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
05:10pm, Monday, 11'th Jan 2021
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Offic
Why Mesoblast Stock Skyrocketed Today
04:43pm, Monday, 11'th Jan 2021
The company announced positive results from a clinical trial.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from
Why Mesoblast Stock Plummeted on Friday
04:46pm, Friday, 18'th Dec 2020
Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.
Mesoblast Webcast – Update on COVID-19 ARDS Trial
10:07pm, Thursday, 17'th Dec 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an
Mesoblast Update on COVID-19 ARDS Trial
06:32pm, Thursday, 17'th Dec 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with
Why Mesoblast Stock Is Tanking Today
12:56pm, Tuesday, 15'th Dec 2020
The company reported disappointing results from a late-stage clinical study.
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure
05:27pm, Monday, 14'th Dec 2020
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from th
Mesoblast Corporate Update
04:56pm, Monday, 14'th Dec 2020
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a c
New York, New York--(Newsfile Corp. - December 7, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) alle
New York, New York--(Newsfile Corp. - December 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Li
